Sorrento and Mount Sinai Health System Enter Into Exclusive License Agreement for Development of Potent Antibody Combinations Aimed at Neutralizing SARS-CoV-2 and the Emerging United Kingdom and South Africa Variants of COVID-19
March 09, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Sorrento is moving forward with the research and development of COVISHIELD antibody combinations with potentially potent neutralizing activities against early COVID-19 pandemic virus isolates as well...